



## Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

November 4, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2024-- [Amylyx Pharmaceuticals, Inc.](#) (Nasdaq: AMLX) ("Amylyx" or the "Company") will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.

To access the conference call, please dial +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, <https://investors.amylyx.com/events-presentations>. The webcast will be archived and available for replay for 90 days following the event.

### About Amylyx Pharmaceuticals

Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit [amylyx.com](https://amylyx.com) and follow us on [LinkedIn](#) and [X](#). For investors, please visit [investors.amylyx.com](https://investors.amylyx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241104724721/en/): <https://www.businesswire.com/news/home/20241104724721/en/>

#### Media

Amylyx Media Team  
+1 (857) 799-7274  
[amylyxmediateam@amylyx.com](mailto:amylyxmediateam@amylyx.com)

#### Investors

Lindsey Allen  
Amylyx Pharmaceuticals, Inc.  
+1 (857) 320-6244  
[Investors@amylyx.com](mailto:Investors@amylyx.com)

Source: Amylyx Pharmaceuticals, Inc.